These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Thiele SL; Chen B; Lo C; Gertler TS; Warre R; Surmeier JD; Brotchie JM; Nash JE Neurobiol Dis; 2014 Nov; 71():334-44. PubMed ID: 25171793 [TBL] [Abstract][Full Text] [Related]
11. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. Lindenbach D; Ostock CY; Eskow Jaunarajs KL; Dupre KB; Barnum CJ; Bhide N; Bishop C J Pharmacol Exp Ther; 2011 Jun; 337(3):755-65. PubMed ID: 21402691 [TBL] [Abstract][Full Text] [Related]
12. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Picconi B; Centonze D; Håkansson K; Bernardi G; Greengard P; Fisone G; Cenci MA; Calabresi P Nat Neurosci; 2003 May; 6(5):501-6. PubMed ID: 12665799 [TBL] [Abstract][Full Text] [Related]
13. Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine. Ye T; Bartlett MJ; Sherman SJ; Falk T; Cowen SL Exp Neurol; 2021 Jun; 340():113670. PubMed ID: 33662379 [TBL] [Abstract][Full Text] [Related]
14. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Belujon P; Lodge DJ; Grace AA Mov Disord; 2010 Aug; 25(11):1568-76. PubMed ID: 20623773 [TBL] [Abstract][Full Text] [Related]
15. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats. Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117 [TBL] [Abstract][Full Text] [Related]
16. A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia. Calabrese V; Picconi B; Heck N; Campanelli F; Natale G; Marino G; Sciaccaluga M; Ghiglieri V; Tozzi A; Anceaume E; Cuoc E; Caboche J; Conquet F; Calabresi P; Charvin D Neuropharmacology; 2022 Nov; 218():109205. PubMed ID: 35940348 [TBL] [Abstract][Full Text] [Related]
17. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101 [TBL] [Abstract][Full Text] [Related]
18. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements. Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790 [TBL] [Abstract][Full Text] [Related]
19. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846 [TBL] [Abstract][Full Text] [Related]